Epidarex Closes £102m Fund To Back Budding UK Biotechs
Venture Firm Helping University Spin-Outs
The UK government is putting £50m into a fund that is aiming to build new life science companies based on world-class research and innovation from emerging hubs across the country.
You may also be interested in...
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.
The Swiss major's pharma chief Bill Anderson tells Scrip that the goal for the firm over the next decade is to deliver twice as many medicines at a much lower cost to society.